SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
PTC Therapeutics, Inc. Initiates Open-Label Study for Ataluren in Patients with Nonsense Mutation Duchenne/Becker Muscular Dystrophy